BioCentury | Jul 26, 2010
Company News

Genzyme sales and marketing update

Genzyme said that as of July 21, it had enrolled 122 late-onset Pompe's disease patients in its Alglucosidase Alfa Control and Education (ACE) program, most of whom had previously been enrolled in its alglucosidase alfa...
BioCentury | Dec 7, 2009

Ebb & Flow

The latest follow-on from Human Genome Sciences Inc. (NASDAQ:HGSI) will increase its cash to around $1.1 billion, more than enough to get Benlysta belimumab to market for systemic lupus erythematosus. Indeed, if all goes well,...
BioCentury | Dec 7, 2009
Clinical News

Alglucosidase alfa: Expanded access program restarted

Genzyme also said it would reopen U.S. enrollment in the alglucosidase alfa temporary access program (ATAP) that will provide the drug product being manufactured at a 4,000L facility in Geel, Belgium. The company closed the...
BioCentury | Dec 4, 2009
Company News

Genzyme to resubmit Lumizyme BLA

Genzyme Corp . (NASDAQ:GENZ) said it expects to resubmit a BLA for Lumizyme alglucosidase alfa for Pompe's disease by year end, seeking approval of the product produced at the 4,000L bioreactor scale at its facility in...
Items per page:
1 - 4 of 4